Last update 21 Nov 2024

Iothalamate Sodium

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Iothalamate sodium (USP), Sodium iotalamate (JP17), ANGIO-CONRAY

+ [3]

Target-

Mechanism-

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Mallinckrodt Medical, Inc. (US)

Active Organization-

Inactive Organization

Mallinckrodt Medical, Inc. (US)

Drug Highest PhaseWithdrawn

First Approval Date

US (30 Sep 1963)

Regulation-

Structure

Molecular FormulaC11H9I3N2NaO4

InChIKeyMEXSLGBZRYTOAI-UHFFFAOYSA-N

CAS Registry1225-20-3

View All Structures (2)

100 Clinical Results associated with Iothalamate Sodium

100 Translational Medicine associated with Iothalamate Sodium

100 Patents (Medical) associated with Iothalamate Sodium

233

Literatures (Medical) associated with Iothalamate Sodium

01 Dec 2016·Clinica Chimica ActaQ3 · MEDICINE

A simple LC-MS method for the determination of iohexol and iothalamate in serum, using ioversol as an internal standard

Q3 · MEDICINE

Article

Author: Peeters, Stéphanie ; Nyssen, Laurent ; Cavalier, Étienne ; Le Goff, Caroline ; Delanaye, Pierre

BACKGROUNDChronic kidney disease (CKD) is diagnosed and explored through the determination of the glomerular filtration rate (GFR). Our goal was to develop a simple LC-MS method for the determination in serum of 2 popular GFR markers, contrast agents iohexol and iothalamate, for routine use and comparison studies between the two markers. A similar contrast agent, ioversol, was used as an internal standard and the method underwent a rigorous validation protocol based on β-expectation tolerance intervals.METHODSWe adapted the HPLC-UV method from Cavalier et al. to our LC-MS system. Data treatment for the validation was performed using Multiquant 3.0 (Sciex, Framingham, MA, USA) and e.noval 3.0 software (Arlenda, Liège, Belgium).RESULTSAccording to the validation results our method will give accurate and reliable results for concentrations ranging from 6.8 to 250μg/ml for iohexol and 6.15μg/ml to 250μg/ml for iothalamate. In our practice these intervals are sufficient to determine both compounds in most patient samples. Samples with higher detected concentrations can always be diluted into range.CONCLUSIONWith its internal standard and extensive validation, our method is now ready for routine and clinical research use.

01 Sep 2016·ELECTROPHORESISQ3 · BIOLOGY

Determination of iohexol and iothalamate in serum and urine by capillary electrophoresis

Q3 · BIOLOGY

Article

Author: Lecocq, Elke ; Seaux, Liesbeth ; Dumoulin, Els ; Speeckaert, Marijn M. ; Van Houcke, Sofie K. ; Cavalier, Etienne ; Delanghe, Joris R.

Estimation of glomerular filtration rate (eGFR) is essential to assess kidney function. Iodine‐containing contrast agents detection by HPLC has been proposed as a safe alternative for inulin or radioactive compounds. However, HPLC is a time‐consuming and labor‐intensive method. The aim of this study was to develop an assay for iohexol and iothalamate using capillary electrophoresis. Iohexol and iothalamate were directly analyzed by CE in serum and urine, using photometric detection (246 nm). Serum peak height was proportional to iohexol and iothalamate concentrations. Detection limits for iohexol and iothalamate were 10 and 5 mg/L. Limits of quantification were 13.0 and 15.0 mg/L. Within‐run CVs were 4.9 and 6.5%; between‐run CVs 3.1–9.9% and 3.8–13.7%. A good correlation was observed between CE and HPLC: y = 1.1703x + 5.017 (iohexol) and y = 0.7807x + 11.01 (iothalamate; (y = concentration obtained by CE [mg/L], x = concentration obtained by HPLC [mg/L]). In addition, CE allowed to determine urinary iohexol concentration. Although the detection limit for CE was higher than for HPLC, CE can still be used for eGFR determination. Advantages of this high‐throughput method are the absence of sample pretreatment and a minimal sample volume requirement.

01 Jun 2016·American Journal of Kidney Diseases

Iohexol Versus Iothalamate for GFR Measurement

Letter

Author: Sterner, Gunnar ; Bäck, Sten-Erik ; Nyman, Ulf

100 Deals associated with Iothalamate Sodium

External Link

KEGG	Wiki	ATC	Drug Bank
D03603	Iothalamate Sodium	V08AA04	DB09133

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASN2010	Not Applicable	-	150	Iothalamate	mddwqhrmfo(xuefsfdloi) = slhdwwlfyb sulpwuisqp (hqlqgbcqed )	-	16 Nov 2010
				Iothalamate	mddwqhrmfo(xuefsfdloi) = qwimltjuok sulpwuisqp (hqlqgbcqed, -14.7% (-16.3% - -13.0%))

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Iothalamate Sodium

Overview

Basic Info

Structure

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation